Exchange Traded Concepts LLC lessened its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 88.1% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 38,158 shares of the company's stock after selling 281,524 shares during the period. Exchange Traded Concepts LLC owned about 0.08% of Omnicell worth $1,334,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Smartleaf Asset Management LLC lifted its position in shares of Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after purchasing an additional 273 shares during the period. Johnson Financial Group Inc. purchased a new stake in shares of Omnicell in the 4th quarter worth approximately $37,000. Van ECK Associates Corp lifted its position in shares of Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after purchasing an additional 315 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Omnicell in the 4th quarter worth approximately $53,000. Finally, First Horizon Advisors Inc. lifted its position in shares of Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after purchasing an additional 355 shares during the period. Hedge funds and other institutional investors own 97.70% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts recently commented on OMCL shares. Benchmark decreased their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Wall Street Zen raised shares of Omnicell from a "hold" rating to a "buy" rating in a research report on Tuesday, May 20th. Piper Sandler reissued an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. Wells Fargo & Company reissued an "overweight" rating and set a $37.00 target price (up previously from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. Finally, JPMorgan Chase & Co. decreased their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, March 20th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Omnicell currently has an average rating of "Moderate Buy" and a consensus target price of $44.83.
Get Our Latest Stock Analysis on Omnicell
Omnicell Trading Down 0.8%
Shares of Omnicell stock opened at $28.27 on Thursday. The company has a current ratio of 1.38, a quick ratio of 1.23 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.75. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of 61.46 and a beta of 0.78. The firm's 50 day simple moving average is $29.57 and its two-hundred day simple moving average is $36.69.
Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.10. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. The business had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. During the same quarter in the prior year, the business posted $0.03 EPS. Omnicell's revenue for the quarter was up 9.5% compared to the same quarter last year. Analysts predict that Omnicell, Inc. will post 1.09 EPS for the current year.
Omnicell Company Profile
(
Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
See Also
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
